Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical leader developing oral peptide therapies for inflammatory and hematologic conditions. This news hub provides investors and researchers with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access timely announcements about PTGX's innovative constrained peptide platform and pipeline candidates like icotrokinra (IL-23 antagonist) and rusfertide (hepcidin mimetic). Our curated collection includes press releases on trial results, FDA communications, and collaborations with industry leaders including Johnson & Johnson.
Key updates cover therapeutic advancements for psoriasis, ulcerative colitis, and polycythemia vera. Bookmark this page to monitor Protagonist's progress in transforming biologic-like treatments into oral formulations while maintaining competitive positioning through proprietary drug discovery methods.
Protagonist Therapeutics (NASDAQ:PTGX) announced a public offering of $100 million in common stock, with a 30-day option for underwriters to purchase an additional $15 million. The proceeds will fund clinical development of rusfertide and general corporate purposes. The offering is subject to market conditions, with no guarantee of completion or terms. Jointly managed by J.P. Morgan, Jefferies, and Piper Sandler, the offering's registration statement became effective on August 16, 2022. Interested investors should consult the SEC's website for the prospectus.
Protagonist Therapeutics (PTGX) reported positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 for moderate-to-severe psoriasis and the REVIVE study of rusfertide for polycythemia vera, achieving significant endpoints. The FRONTIER 1 study demonstrated a greater proportion of patients achieving PASI-75 responses compared to placebo, with no significant adverse events noted. Financially, Protagonist ended 2022 with $237.4 million in cash, sufficient to fund operations through 2024, despite a net loss of $127.4 million for the year. They are preparing for a Phase 3 study of rusfertide, with potential milestone payments of up to $855 million.
Protagonist Therapeutics (NASDAQ:PTGX) announced positive topline results from the REVIVE study on rusfertide, demonstrating significant improvement in responders (69.2% for rusfertide vs. 18.5% for placebo; p=0.0003). The study focused on patients with polycythemia vera, revealing that 92.3% of rusfertide subjects remained phlebotomy-free. Rusfertide showed no new safety signals and was well tolerated. The results support rusfertide's potential as a transformative option for PV treatment. The company is prioritizing the Phase 3 VERIFY study, aiming to expand its development pipeline for this promising therapeutic.
Protagonist Therapeutics (PTGX) announced positive topline results from the FRONTIER 1 Phase 2b trial of JNJ-2113, an oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis. The study involved 255 patients, showing that JNJ-2113 met its primary endpoint with a statistically significant improvement (PASI-75) at Week 16 compared to placebo across all treatment groups. Treatment was well tolerated, with no notable differences in adverse events. Protagonist anticipates progressing JNJ-2113 to Phase 3 trials, aiming for milestone payments of up to $855 million from its collaboration with Janssen Biotech.
Protagonist Therapeutics (Nasdaq: PTGX) announced that CEO Dinesh V. Patel will present at the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. The presentation is scheduled for January 11 at 7:30 a.m. PT, held at the Westin St. Francis. Protagonist is advancing its lead drug candidate, rusfertide, for polycythemia vera in a global Phase 3 trial, alongside a partnership with Janssen Biotech for PN-235, aimed at treating psoriasis and inflammatory bowel diseases. A webcast will be available on the company’s investor website.
Protagonist Therapeutics (Nasdaq: PTGX) announced that Dr. Dinesh V. Patel, President and CEO, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit from December 6-7, 2022. The chat is scheduled for December 6, 2022, at 11:40 a.m. ET. A webcast will be accessible for 90 days on Protagonist's Investors section. The company is advancing its lead drug candidate, rusfertide, in a global Phase 3 study for polycythemia vera, and has partnered with Janssen Biotech on PN-235 for psoriasis and inflammatory bowel disease.
Protagonist Therapeutics (PTGX) announced the granting of inducement awards to Dr. Arturo Molina, its new Chief Medical Officer, on November 15, 2022. Dr. Molina received options to purchase 127,500 shares and restricted stock units for 21,250 shares, with an exercise price of $8.04 per share. The options and RSUs will vest over four years. This award aligns with Nasdaq rules and emphasizes the company's commitment to attract key talent. Protagonist is advancing its drug candidate rusfertide in a Phase 3 study for polycythemia vera, alongside a partnership with Janssen for the development of PN-235.
Protagonist Therapeutics (Nasdaq: PTGX) continues its Phase 3 VERIFY clinical study of rusfertide for polycythemia vera (PV) amidst operational hiring challenges. Dr. Arturo Molina has been appointed as the new Chief Medical Officer to enhance clinical development efforts. The company plans to present three posters at the ASH Annual Meeting in December. Financially, Protagonist reported a net loss of $31.2 million in Q3 2022, with cash and equivalents of $267.4 million expected to cover operations through 2024. Revenue from collaboration agreements decreased significantly.
Protagonist Therapeutics (PTGX) announced that three abstracts related to its rusfertide program will be presented at the 64th Annual ASH Meeting from December 10-13, 2022, in New Orleans. The presentations include a Phase 3 study on rusfertide in patients with Polycythemia Vera (VERIFY), a Phase 2 subgroup analysis of adverse events (REVIVE), and an efficacy study of a rusfertide analog in a mouse model for hereditary hemochromatosis. Protagonist owns marketing rights to rusfertide, which is in the final stages of clinical development.
Protagonist Therapeutics has appointed Dr. Arturo Molina as Chief Medical Officer, effective November 7, 2022. Dr. Molina, an accomplished hematologist-oncologist, will lead the Phase 3 VERIFY study of rusfertide for polycythemia vera and enhance the company’s clinical and operational strategies. His prior experience includes roles at Sutro Biopharma and Johnson & Johnson, underscoring a strong track record in clinical development. The focus on rusfertide's potential to transform treatment highlights the company’s commitment to advancing innovative therapies.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
